A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes
Version of Record online: 19 OCT 2013
© 2013, The American College of Clinical Pharmacology
The Journal of Clinical Pharmacology
Volume 54, Issue 3, pages 267–278, March 2014
How to Cite
Wilkins, J. J., Dubar, M., Sébastien, B. and Laveille, C. (2014), A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. Journal of Clinical Pharma, 54: 267–278. doi: 10.1002/jcph.192
- Issue online: 11 FEB 2014
- Version of Record online: 19 OCT 2013
- Accepted manuscript online: 3 OCT 2013 10:13AM EST
- Manuscript Accepted: 19 SEP 2013
- Manuscript Received: 12 AUG 2013
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Table S1. Final Parameter Estimates for the Model for FPG and FSI After Inclusion of External Validation Data
Table S2. Final Parameter Estimates for the Model for HbA1c After Inclusion of External Validation Data
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.